Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.
Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Echo Warner, MPH, PhD, SB
- Número de teléfono: 801-244-7040
- Correo electrónico: echo.warner@hci.utah.edu
Ubicaciones de estudio
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Reclutamiento
- University of Utah
-
Contacto:
- Echo Warner, MPH, PhD, SB
- Número de teléfono: 801-244-7040
- Correo electrónico: echo.warner@hci.utah.edu
-
Investigador principal:
- Echo Warner, MPH, PhD, SB
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
- Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
- At the time of enrollment, have not completed all recommended doses of the HPV vaccine.
Exclusion Criteria:
- Unable to speak and understand English.
- Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
- Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: HPV Vaccination Education
Microvideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner.
HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention.
|
To educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination.
The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility of Microvideo education
Periodo de tiempo: up to 4 weeks
|
Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.
|
up to 4 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Acceptability of Microvideo Education
Periodo de tiempo: up to 4 weeks
|
Acceptability will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
Satisfaction Acceptability of Microvideo Education
Periodo de tiempo: up to 4 weeks
|
Satisfaction will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
HPV Vaccine Intention
Periodo de tiempo: up to 4 weeks
|
To assess HPV vaccine intention among unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. This outcome measure will report the count of participants who intended to receive the HPV Vaccine after the microvideo education. |
up to 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Echo Warner, MPH, PhD, SB, Huntsman Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 198894
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .